Search
INCY; NLNK: IDO Inhibitor Yervoy combo ineffective after immunotherapy and half the efficacy of Opdi
Early IDO data disappointing for both Incyte and Roche Partners NewLink:
IDO inhibition is one of many newer immunotherapies that are beginning to enter clinical trials. Data from a study Inhibiting the IDO1 enzyme (which is thought to supress immune T‑ cells from killing cancer) with Incyte’s IDO inhibitor INCB024360 (epacadostat) combined with Yervoy in Melanoma was released in the ECC abstracts
